Comparative Pharmacology
Head-to-head clinical analysis: KADIAN versus NORCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADIAN versus NORCET.
KADIAN vs NORCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Combination analgesic: hydrocodone acts as a μ-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system, exerting central analgesic and antipyretic effects.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
1-2 tablets (containing paracetamol 325 mg and tramadol 37.5 mg) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
2-4 hours (terminal); prolonged in hepatic impairment (up to 8-10 hours) and elderly
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Renal: ~60% unchanged; hepatic metabolism to inactive glucuronide conjugates; biliary/fecal: <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic